Durham Pharmaceutical Manufacturer Merger Announced

MedPharm, a global contract development and manufacturing organization or CDMO, has merged with Tergus Pharma, enhancing its presence in South Durham. The combined organization, operating under the MedPharm name, aims to be a leading CDMO with comprehensive capabilities in scientific, clinical trial manufacturing, and commercial production.

The merger will expand MedPharm’s services, including the development and manufacture of hormone-based and highly potent drugs at its manufacturing facility in Durham. Michael Kane, the CEO of Tergus Pharma, will take over as CEO of MedPharm, while Patrick Walsh will continue as executive chairman.

“This strategic partnership is an exciting opportunity to deliver extensive pharmaceutical product development resources,” Kane said. “With locations in both the United Kingdom and the United States, we are well positioned to provide exceptional support to our existing and prospective pharmaceutical clients.”

Walsh added: “Pharma clients have been seeking a reliable, integrated service offering for their ophthalmic, topical, and transdermal development and manufacturing projects. This merger creates an immediate option with two organizations already well-positioned in the industry.”

Great Point Partners, Tergus’s lead investor, will retain a significant minority ownership stake in the new MedPharm, while Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership.

Southpoint Access is a free community news website run as a service to our neighbors in South Durham. Please consider supporting us as a subscriber on Patreon or donate to underwrite the cost of covering the news that matters to you in neighborhoods like Woodcroft, Parkwood, Fairfield, and Hope Valley Farms.